NOXXON’s oncology-focused pipeline acts by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the tumor micro-environment (TME), NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, lead program NOX-A12 has delivered top-line data from a combination trial with the immuno-oncology checkpoint inhibitor, Keytruda®, in metastatic colorectal and pancreatic cancer patients with the latest update published in April 2020; further studies are being planned in these indications. In September 2019 NOXXON initiated an additional trial of NOX-A12 in brain cancer in combination with radiotherapy. The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. The company’s second clinical-stage asset, NOX-E36 is a Phase 2 ready TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors both as a monotherapy and in combination.


• Download the initiation report on NOXXON by Arrowhead
➥ See all reports on NOXXON here


Press Release

Berlin, Germany

2020, July 24
8:00 a.m.

NOXXON announces first brain cancer patient from second dose cohort reaches 4 weeks of treatment with NOX-A12 combined with radiotherapy

2020, July 13
6:00 p.m.

Half-yearly report on the liquidity contract with Invest Securities

2020, July 02
8:00 a.m.

NOXXON announces appointment of Oscar Izeboud to the supervisory board and provides results of the annual general shareholders meeting


Niels Halama
2019, April 27

Webcast: ESMO Congress 2019 Poster Presentation
-download poster
-download presentation
-view webinar recording

Aram Mangasarian, Jarl Ulf Jungnelius
2019, September 30 | Barcelona, Spain